Agents and Actions

, Volume 28, Issue 3–4, pp 279–282 | Cite as

The effect of the anabolic steroid, stanozolol, on the production of procollagenase by human synovial and skin fibroblastsin vitro

  • J. K. Wright
  • A. J. Smith
  • T. E. Cawston
  • B. L. Hazleman
Inflammation and Immunomodulation Meeting Report

Abstract

The ability of the anabolic steroid, stanozolol, to stimulate procollagenase production by human synovial and skin fibroblasts was examined in anin vitro assay system. Stanozolol is used therapeutically to treat a variety of connective tissue and vascular disorders and its clinical effects suggest that it can modulate connective tissue breakdown. The results showed that stanozolol was capable in a dose dependent manner, of significantly stimulating procollagenase production by skin fibroblasts. However, in three synovial fibroblast lines no evidence was found of increased collagenase production following treatment with stanozolol; although the synovial fibroblasts secreted significantly increased amounts of procollagenase in response to IL-1. These results may shed some light on the mechanism of actionin vivo of stanozolol in the treatment of connective tissue disorders.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    F. E. Preston,The effect of stanozolol on the fibrinolytic enzyme system in normal adults. Scott. Med. J.,Suppl. 59–63 (1981).Google Scholar
  2. [2]
    K. Burnand, G. Clemenson M. Morland, P. E. M. Jarrett and N. L. BrowseVenous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. Br. Med. J.280, 7–11 (1980).PubMedGoogle Scholar
  3. [3]
    J. F. Davidson, M. Lockhead, G. A. McDonald and G. P. McNicol,Fibrinolytic enhancement by stanozolol: a double blind trial. Br. J. Haematol.22, 543–559 (1972).PubMedGoogle Scholar
  4. [4]
    P. E. M. Jarrett, M. Morland and N. L. Browse,Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br. Med. J.2, 523–525 (1978).PubMedGoogle Scholar
  5. [5]
    C. H. Chesnut, J. L. Ivey, H. E. Gruber, M. Matthews, W. B. Nelp, K. Sisom and D. J. Baylink,Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanism of action. Metabolism32, 571–580 (1983).PubMedGoogle Scholar
  6. [6]
    J. J. F. Belch, R. Madhok, B. McArdle, K. McLaughlin, C. Kluft, C. D. Forbes and R. D. Sturrock,The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Quart. J. Med.58, 19–27 (1986).PubMedGoogle Scholar
  7. [7]
    J. J. F. Belch, B. McArdle, R. Madhok, K. McLaughlin, H. A. Cappell, C. D. Forbes and R. D. Sturrock,Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann. Rheum. Dis.43, 774–779 (1984).PubMedGoogle Scholar
  8. [8]
    M. Couch, F. E. Preston, R. G. Malia and R. G. G. Russell,Changes in plasma osteocalcin concentration following treatment with stanozolol. Clin. Chim. Acta158, 43–47 (1986).PubMedGoogle Scholar
  9. [9]
    J. N. Beresford, J. A. Gallagher J. Poser, M. Gowen, M. Couch, A. J. P. Yates, J. A. Kanis and R. G. G. Russell,Effects of the anabolic steroid, stanozolol, on human bone cells in vitro. Calcified Tissue Int.35, Suppl. A25 (1983).Google Scholar
  10. [10]
    J. A. Gallagher, J. N. Beresford, M. K. B. McGuire, N. M. Ebsworth, J. E. Meats, M. Gowan, P. Elford, D. Wright, J. Poser, L. A. Coulton, M. Sharrard, B. Imbimbo and R. G. G. Russell,Effects of glucocorticoids and anabolic steroids on cells derived from human skeletal and articular tissues in vitro. Adv. Exp. Med. Biol.171, 279–291 (1984).PubMedGoogle Scholar
  11. [11]
    P. R. Elford, J. E. Meats and R. G. G. Russell,Effect of glucocorticosteroids, stanozolol and sex hormones on production of plasminogen activator by human articular chondrocytes. Calcified Tiss. Int.35, Suppl. A25 (1983).Google Scholar
  12. [12]
    J. M. Dayer, S. M. Krane, R. G. G. Russell and D. R. Robinson,Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Nat. Acad. Sci. USA73, 945–949 (1976).PubMedGoogle Scholar
  13. [13]
    J. M. Dayer and S. Demezuk,Cytokines and other mediators in rheumatoid arthritis. Springer Semin. Immunopathol.7, 387–413 (1984).PubMedGoogle Scholar
  14. [14]
    J. A. Hamilton and J. Slywka.Stimulation of human synovial fibroblast plasminogen activator production by mono-nuclear cell supernatants. J. Immunol.126, 851–855 (1981).PubMedGoogle Scholar
  15. [15]
    J. M. Dayer, B. Rochemonteix, B. Burrus, S. Demczuk and C. A. Dinarello,Human recombinant interleukin 1 stimulates collagenase and prostaglandin E 2 production by human synovial cells. J. Clin. Invest.77, 645–648 (1986).PubMedGoogle Scholar
  16. [16]
    T. E. Cawston, E. Mercer and J. A. Tyler,The activation of latent pig synovial collagenase. Biochim. Biophys. Acta657, 73–83 (1981).PubMedGoogle Scholar
  17. [17]
    E. D. Harris, J. M. Evanson, D. R. DiBona and S. M. Krane,Collagenase and rheumatoid arthritis. Arthritis Rheum.13, 83–94 (1970).PubMedGoogle Scholar
  18. [18]
    M. D. Chard, J. K. Wright and B. L. Hazleman,Isolation and growth characteristics of adult human tendon fibroblasts. Ann. Rheum Dis.46, 385–390 (1987).PubMedGoogle Scholar
  19. [19]
    T. E. Cawston and A. J. Barrett,A rapid and reproducible assay for collagenase using 1- 14 C acetylated collagen. Anal. Biochem.99, 340–345 (1979).PubMedGoogle Scholar
  20. [20]
    M. I. V. Jayson, A. L. Keegan, C. D. Holland, J. Longstaff, L. Taylor and R. Gush,A study of stanozolol therapy for systemic sclerosis and Raynaud's Phenomenon. Haemostasis14, 53a (1984).Google Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • J. K. Wright
    • 1
  • A. J. Smith
    • 1
  • T. E. Cawston
    • 1
  • B. L. Hazleman
    • 1
  1. 1.Rheumatology Research UnitAddenbrooke's HospitalCambridgeUK

Personalised recommendations